benign prostate hyperplasia

mmustafa's picture

The Ethnic And Geographic Variation In The Diagnostic Values of Prostate Specific Antigen And Its Derivatives In Detecting Prostate Cancer

Journal Title, Volume, Page: 
The New Journal of Urology 2009, 5 (1): 27-30
Year of Publication: 
2009
Authors: 
Mahmoud Mustafa
Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
Current Affiliation: 
Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
Bedier Ali-El-Dien
Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
Tarek Mohsen
Department of Radiology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
El-Housseiny I. Ibrahiem
Department of Urology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
Preferred Abstract (Original): 

Objeetive: To evaluate the diagnostic value of prostate specific antigen (PSA) and its derivatives in detecting prostate cancer at biopsies. Materials and methods: Between July 2004 and March 2005, 1,05patients who underwent transrectal ultrasound-guided (TRUSO) systemic sextant core biopsies were included. All patients had PSA values 4-20 ng/ml ± abnormal digital rectal examinations (DRE) findings. PSA density (PSAD) and PSA density of the transition zone(TZPSAD) were calculated for each patient. Comparison between the clinical variables of patients with prostate cancer and benign prostatic hyperplasia (BPH) in terms of TPSA, total volume, TPSAD, TZPSAD, TRUS findings and DRE findings, "vas done. The diagnostic value of TRUS and DRE were also evaluated. Results: Out of 105 patients 11 had prostatic cancer (10.47%). There was no significant difference between subjects with BPH and subjects with prostate cancer in terms of total prostate volume, TPSA values, TRUS findings and DRE findings. However the values ofTPSAD and TZPSAD for patients with BPH differs significantly from that of patients with prostate cancer (P = 0.0001, P = 0.009 respectively). The accuracy ofDRE and TRUSO were 59.04% and 50.470/0respectively, both of them are poor predictors with insignificant difference (P= 0.25). Conclusion: Total PSA is of no diagnostic value in detecting prostate cancer in Egyptian patients with PSA < 20 ng/ml. However TPSAD and TZPSAD could be considered as accurate parameters with clinical significant for prostate cancer prediction in patients with PSA below 20 ng/ml. TRUS and DRE are poor predictor of prostate cancer with no significant difference.

Syndicate content